8-K: Allarity Therapeutics Presents Drug Response Predictor for Daratumumab in Multiple Myeloma at AACR 2025

Allarity Therapeutics announces the presentation of a poster at the AACR 2025 Annual Meeting showcasing a novel Drug Response Predictor (DRP) designed to identify multiple myeloma patients likely to benefit from daratumumab.

Summary

• Allarity Therapeutics presented data on a new Drug Response Predictor (DRP) for daratumumab at the 2025 American Association for Cancer Research (AACR) Annual Meeting.
• The DRP is designed to identify multiple myeloma patients most likely to benefit from daratumumab.
• The daratumumab DRP was developed by correlating gene expression patterns with sensitivity to daratumumab-induced antibody-dependent cellular cytotoxicity (ADCC).
• The analysis identified 53 genes, with 27 associated with sensitivity and 26 with resistance, forming the basis of the DRP.
• Using data from the KYDAR trial, the DRP was able to predict treatment outcomes and survival.
• The company already offers an extensive portfolio of DRPs for research use.
• The poster will be made available on Allarity's website later today, following 1:00 p.m. ET, in the Scientific Publications section.

Sentiment

Score: 7

Explanation: The announcement is positive as it highlights the development of a new DRP and its potential to improve patient selection for daratumumab treatment. However, it is still in the research stage and faces risks related to validation and commercialization.

Positives

• The development of a DRP for daratumumab expands Allarity's DRP platform to include antibody therapies.
• The DRP has the potential to improve patient selection for daratumumab treatment in multiple myeloma.
• The DRP was able to predict treatment outcomes and survival using data from the KYDAR trial.
• The company already offers an extensive portfolio of DRPs for research use.
• The development of the DRP positions Allarity as a potential strategic partner for companies seeking to target the right patients with existing cancer therapies.

Risks

• The daratumumab DRP may not be further validated or accepted for clinical use.
• The predictive capabilities of the DRP may not be confirmed in larger or independent datasets.
• Allarity may not be able to secure partnerships or commercial applications for the DRP.
• The technology is still in the research stage.

Future Outlook

Allarity intends to leverage the daratumumab DRP for potential future collaborations aimed at bringing precision diagnostics to more patients and positions them as a potential strategic partner for any third party seeking to target the right patients with existing cancer therapies.

Management Comments

• Thomas Jensen, CEO of Allarity Therapeutics, stated that this is another successful application of their DRP technology beyond their internal clinical program pipeline.
• Thomas Jensen, CEO of Allarity Therapeutics, stated that the addition of a DRP for daratumumab further demonstrates the versatility and flexibility of their DRP platform.

Industry Context

The development of a DRP for daratumumab aligns with the growing trend of personalized medicine in oncology, where treatments are tailored to individual patients based on their unique genetic profiles. This approach aims to improve treatment outcomes and reduce unnecessary side effects.

Comparison to Industry Standards

• Several companies are developing companion diagnostics to predict drug response in cancer patients.
• For example, Foundation Medicine offers comprehensive genomic profiling services to identify patients who may benefit from specific targeted therapies.
• Qiagen also develops and markets companion diagnostics for various cancer drugs.
• Allarity's DRP technology differentiates itself by focusing on mRNA expression profiles and incorporating clinical tumor biology filters and prior clinical trial outcomes.

Stakeholder Impact

• Shareholders may view the development of the daratumumab DRP as a positive step for the company.
• Patients with multiple myeloma may benefit from improved treatment selection based on the DRP.
• Potential partners may be interested in collaborating with Allarity to leverage the DRP technology.

Next Steps

• Allarity will make the poster available on its website.
• The company intends to pursue potential future collaborations to bring precision diagnostics to more patients.
• Further validation of the daratumumab DRP in larger or independent datasets.

Key Dates

Keywords

Allarity Therapeutics, Daratumumab, Drug Response Predictor, DRP, Multiple Myeloma, AACR 2025, Personalized Cancer Treatment, Stenoparib, Biomarker, Oncology